reference/24426480

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24426480

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial
endingPage	168
issn	1791-2431 1021-335X
issueIdentifier	1
pageRange	159-168
publicationName	Oncology Reports
startingPage	159
bibliographicCitation	Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K, Matsumoto H, Fukasawa S, Kohjimoto Y, Nakatsu H, Takenaka A, Fujisawa M, Uemura H, Naito S, Egawa S, Fujimoto H, Hinotsu S, Itoh K. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel. Oncol Rep. 2021 Jan;45(1):159–68. PMID: 33200227; PMCID: PMC7709822.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37ef83176a82198a5a9331894abd949a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d7805506009c68fe581679afa7571a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4759-4999 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_daf08c0618fdbb78590ab6383bdc407c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2328-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbf8893310fced62e2644d3a42352e44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ab416c25997a82a18fe861054a0ccee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee4416f4877b412d5ca4e3fb7156c394 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8300fdf109780702dda956ce46a6f3bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_750e27ff50a198843644793502b2e583 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ce042022b0e27540fb6e839f47b0bfd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf3be92d32141049bc4f96749e1e452c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1cba0021265be223b00a3bc81a58578 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a0046c3be5a76aff5fe3a8a9f01a4bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7932f41b3a540028dbb8ac20c00d1eff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bbc7d9f4bb12ada59f100fbd482133d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca9f98f0b823010e41933e0a1374962e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_29ca214d638ac1af7048ac6d61d6bf60
date	2020-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC7709822 https://pubmed.ncbi.nlm.nih.gov/33200227 https://doi.org/10.3892/or.2020.7847
isPartOf	https://portal.issn.org/resource/ISSN/1791-2431 https://portal.issn.org/resource/ISSN/1021-335X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/20608
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel
discusses	http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0028986 http://id.nlm.nih.gov/mesh/M0551830 http://id.nlm.nih.gov/mesh/M0356852
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D064129Q000628 http://id.nlm.nih.gov/mesh/D019496Q000627 http://id.nlm.nih.gov/mesh/D059871Q000032 http://id.nlm.nih.gov/mesh/D000077143Q000627 http://id.nlm.nih.gov/mesh/D014611
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D022223Q000627 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D064129Q000401 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983

Total number of triples: 58.